Nesfatin-1

What is Nesfatin-1?

Nesfatin-1 is an 82-amino-acid peptide produced by post-translational cleavage of the N-terminus of nucleobindin-2 (NUCB2), a 396-residue secretory precursor that also yields nesfatin-2 and nesfatin-3 by prohormone convertase processing — though only nesfatin-1 has demonstrable biological activity. It was identified in October 2006 by Shinsuke Oh-I, Hiroyuki Shimizu, Masatomo Mori, and colleagues at Gunma University Graduate School of Medicine in Japan, in a Nature paper screening hypothalamic genes regulated by peroxisome proliferator-activated receptor (PPAR) modulators. The team reported that NUCB2 mRNA was concentrated in the paraventricular nucleus, supraoptic nucleus, lateral hypothalamus, and arcuate nucleus, that intracerebroventricular nesfatin-1 dose-dependently suppressed dark-phase food intake in rats, and crucially that the anorexigenic effect persisted in leptin-receptor-deficient db/db mice and leptin-deficient ob/ob mice — establishing the peptide as a leptin-independent satiety signal. Subsequent work expanded the anatomical map well beyond the central nervous system: NUCB2/nesfatin-1 immunoreactivity is found in pancreatic islets (predominantly beta cells), gastric oxyntic mucosa (in a distinct ghrelin-co-localizing endocrine cell population), the dorsal motor nucleus of the vagus, adipose tissue, testes, and pituitary, with circulating peptide detectable in human plasma. The receptor for nesfatin-1 has not been definitively cloned and remains formally orphan; pharmacological evidence supports a Gi/o-coupled GPCR distinct from the leptin and melanocortin receptors, with downstream engagement of paraventricular oxytocin neurons and the central melanocortin system. Functionally, nesfatin-1 is anorexigenic (central or peripheral administration suppresses food intake), insulinotropic and anti-hyperglycemic in animal studies, modulates blood pressure and heart rate (typically pressor and bradycardic with central administration), and produces anxiogenic and depressive-like behavior in rodent models. There is no nesfatin-1 therapeutic product in any jurisdiction, and human data are dominated by biomarker-level associations with obesity, type 2 diabetes mellitus, polycystic ovary syndrome, and eating disorders — observational studies whose directional interpretation is genuinely contested.

What Nesfatin-1 Is Investigated For

Nesfatin-1 is an endogenous-biology and drug-target topic, not a peptide consumers take. The strongest evidence is for a hypothalamic anorexigenic role: intracerebroventricular nesfatin-1 reproducibly suppresses food intake in rodents, and the Maejima 2009 Cell Metabolism paper from the Yada laboratory established that this effect requires PVN oxytocin neurons and is propagated through a leptin-independent melanocortin pathway — a mechanistically distinct satiety axis from leptin/POMC signaling. The pancreatic-islet and glucose-homeostasis story is the second best-developed strand: Nakata, Mori, Yada and colleagues showed that nesfatin-1 enhances glucose-stimulated insulin secretion through L-type calcium channels in mouse beta cells, and animal studies of type 2 diabetes models report anti-hyperglycemic effects, though no human trial has translated this. The clinical literature on circulating NUCB2/nesfatin-1 in obesity, T2DM, PCOS, and eating disorders is genuinely mixed — some cohorts show elevated levels, others reduced, and meta-analyses are limited by assay heterogeneity and small sample sizes. The peptide has no FDA-approved indication, no validated therapeutic dosing, and the receptor remains formally orphan — a meaningful translational obstacle. The honest framing is that nesfatin-1 is one of the best-characterized recent additions to the satiety neuropeptide family and a credible target for future obesity and diabetes pharmacology, but it has not entered clinical development.

History & Discovery

Nesfatin-1 was identified in October 2006 by Shinsuke Oh-I, Hiroyuki Shimizu, Tetsurou Satoh, Shuichi Okada, and colleagues working in the laboratory of Masatomo Mori at Gunma University Graduate School of Medicine in Maebashi, Japan, in a paper published in Nature on 12 October 2006. The discovery emerged from a screen for hypothalamic genes regulated by peroxisome proliferator-activated receptor (PPAR) modulators — specifically troglitazone, a thiazolidinedione PPAR-gamma agonist. The team was searching for novel anti-obesity targets and identified nucleobindin-2 (NUCB2) mRNA as upregulated in the paraventricular and supraoptic nuclei of the hypothalamus. They showed that NUCB2 was processed by prohormone convertases into an 82-amino-acid N-terminal peptide they named nesfatin-1 — short for 'NEFA/nucleobindin-2-encoded satiety- and fat-influencing protein' — and that intracerebroventricular nesfatin-1 dose-dependently suppressed dark-phase food intake and reduced body weight in rats. The decisive experiment for the field was demonstrating that the anorexigenic effect persisted in leptin-receptor-deficient db/db mice and leptin-deficient ob/ob mice, establishing nesfatin-1 as a satiety signal that operates independently of the leptin axis — a meaningful addition to a field that had been dominated by leptin/POMC signaling for over a decade. The central mechanism was elaborated by the Toshihiko Yada laboratory at Jichi Medical University. Yuko Maejima, Udval Sedbazar, and colleagues, with collaboration from Mori at Gunma and Tamas Horvath at Yale, showed in their 2009 Cell Metabolism paper that nesfatin-1 activates oxytocin neurons in the paraventricular nucleus, which engage the central melanocortin system to suppress feeding through MC3/MC4 receptors. The Yada-Mori-Horvath paper became the canonical mechanistic reference. Gina Yosten and Willis Samson at Saint Louis University extended this in 2010 by showing that both the anorexigenic and the pressor cardiovascular effects of central nesfatin-1 are reversed by oxytocin receptor antagonism, anchoring oxytocin as the proximate mediator. The peripheral story developed largely from the laboratories of Andreas Stengel and Yvette Tache at UCLA (and, after Stengel's relocation, at Charite Berlin and University of Tubingen), who mapped NUCB2/nesfatin-1 expression in gastric oxyntic mucosa endocrine cells in 2009 (Stengel et al., Endocrinology), characterized the partial overlap with ghrelin-producing X/A-like cells, and over the following decade documented expression in pancreatic islets, adipose tissue, the dorsal motor nucleus of the vagus, the pituitary, and other peripheral tissues. The pancreatic-islet insulinotropic mechanism was established by Masanori Nakata, Masatomo Mori, and Toshihiko Yada in their 2011 paper showing that nesfatin-1 enhances glucose-stimulated insulin secretion through L-type voltage-gated calcium channel-dependent calcium influx in mouse beta cells. The clinical literature developed in parallel, dominated by cross-sectional measurements of plasma NUCB2/nesfatin-1 in obesity, type 2 diabetes, metabolic syndrome, polycystic ovary syndrome (Deniz et al. 2012 and many subsequent studies), and eating disorders (Hofmann, Stengel, and colleagues at Charite, with multiple papers from 2013 onward characterizing elevated nesfatin-1 in anorexia nervosa associated with anxiety severity). The receptor for nesfatin-1, however, has resisted cloning for two decades — pharmacological evidence supports a Gi/o-coupled GPCR distinct from leptin, melanocortin, and oxytocin receptors, but the gene encoding it has not been confirmed. As of 2026, no nesfatin-1-targeted therapeutic has reached approval for any indication, and the field is dominated by physiology and biomarker work rather than receptor pharmacology.

How It Works

Nesfatin-1 is a satiety peptide your body makes from a larger precursor protein called NUCB2. When the brain releases it in the hypothalamus, it tells you to stop eating — but unlike leptin, which works through one well-known receptor, nesfatin-1 uses a different and still-unidentified receptor. It activates oxytocin neurons in a brain region called the paraventricular nucleus, which then engage the melanocortin system to suppress appetite. It also has effects in the pancreas (helping insulin release), in fat tissue, in the stomach, and on the cardiovascular system. It is produced in the brain and in many parts of the body, and circulating levels are altered in conditions like obesity, type 2 diabetes, and polycystic ovary syndrome — though the studies don't always agree on the direction.

Nesfatin-1 is generated by prohormone convertase cleavage of the N-terminus of nucleobindin-2 (NUCB2), a 396-amino-acid secretory protein originally characterized as a calcium- and DNA-binding nuclear factor before its peptide-precursor role was recognized. NUCB2 yields three peptide fragments — nesfatin-1 (residues 1-82), nesfatin-2 (residues 85-163), and nesfatin-3 (residues 166-396) — by cleavage at paired basic residues, with prohormone convertase 1/3 (PC1/3) and PC2 implicated in the processing. Only nesfatin-1 has demonstrable biological activity in feeding paradigms; nesfatin-2 and nesfatin-3 are present but functionally silent in characterized assays. The biologically active core of nesfatin-1 has been mapped to the mid-segment (approximately residues 24-53), which retains anorexigenic activity in fragment studies. The receptor for nesfatin-1 has not been definitively cloned and remains formally orphan. Pharmacological evidence — saturable membrane binding, pertussis-toxin sensitivity, intracellular calcium mobilization, and ERK1/2 activation in responsive cells — points to a Gi/o-coupled rhodopsin-family GPCR distinct from the leptin receptor (LepR), melanocortin receptors (MC3R, MC4R), and the oxytocin receptor. Several candidate receptors have been proposed without confirmation. The orphan status is a meaningful obstacle to drug development. Centrally, nesfatin-1 acts through a leptin-independent hypothalamic-brainstem circuit. In the paraventricular nucleus (PVN), nesfatin-1 activates oxytocin neurons, as established by Maejima, Yada, Mori, and colleagues in their 2009 Cell Metabolism paper. PVN oxytocin neurons project to the brainstem and engage the central melanocortin system at MC3/MC4 receptors in the dorsal vagal complex, generating a satiety signal that suppresses food intake. The Maejima paper formally established leptin-independence by demonstrating preserved anorexigenic activity in leptin-receptor-deficient db/db mice and leptin-deficient ob/ob mice. Yosten and Samson at Saint Louis University extended the oxytocin link by showing that both the anorexigenic and the pressor cardiovascular effects of central nesfatin-1 are reversed by oxytocin receptor antagonism — anchoring oxytocin as the proximate mediator and explaining the coupled feeding and blood-pressure phenotype. Peripherally, NUCB2/nesfatin-1 is expressed in pancreatic islets — predominantly in beta cells, with lower expression in alpha and delta cells — and Nakata, Mori, Yada and colleagues demonstrated in 2011 that nesfatin-1 enhances glucose-stimulated insulin secretion in mouse beta cells through promotion of L-type voltage-gated calcium channel-dependent calcium influx. In rodent type 2 diabetes models, nesfatin-1 administration produces anti-hyperglycemic effects. NUCB2/nesfatin-1 is also expressed in the gastric oxyntic mucosa, in a distinct endocrine cell population that partially overlaps with ghrelin-producing X/A-like cells (characterized by Stengel, Goebel, Tache, and colleagues in their 2009 Endocrinology paper), in the dorsal motor nucleus of the vagus, in subcutaneous and visceral adipose tissue, in testes and pituitary, and in cardiovascular tissues. Circulating NUCB2/nesfatin-1 is detectable in human plasma at concentrations that vary with feeding state and metabolic phenotype, supporting both autocrine/paracrine and endocrine modes of action. Behaviorally, central nesfatin-1 administration produces anxiogenic and depressive-like effects in rodent models, with PVN, central amygdala, and dorsal raphe nucleus all implicated as anatomical substrates. Cardiovascularly, central administration is typically pressor and bradycardic. Stress responsiveness is robust: NUCB2/nesfatin-1 expression in PVN and brainstem is upregulated by acute restraint, water-immersion, and immune stress, and central nesfatin-1 activates the hypothalamic-pituitary-adrenal axis with elevation of plasma corticosterone or cortisol — consistent with a peptide that integrates feeding, stress, and autonomic outflow.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Nesfatin-1:

• 01Identification and cloning of the nesfatin-1 receptor — the most consequential gap in the field. Without a defined receptor, rigorous subtype-selective pharmacology, knockout validation, and rational drug-discovery campaigns are not possible.
• 02Whether circulating NUCB2/nesfatin-1 levels in obesity, type 2 diabetes, polycystic ovary syndrome, and eating disorders reflect compensatory upregulation of a satiety signal, contributory dysregulation, or epiphenomenal change — the directional interpretation has been unresolved for over a decade and limits clinical utility as a biomarker.
• 03Standardization of NUCB2/nesfatin-1 assays — inter-assay heterogeneity is a recognized concern in the literature and a major contributor to inconsistent biomarker findings across cohorts.
• 04Whether the anti-hyperglycemic and insulinotropic effects of nesfatin-1 in rodent type 2 diabetes models translate to human metabolic disease — no interventional human trial has tested this.
• 05The directional balance between nesfatin-1's anorexigenic benefit (potentially desirable in obesity) and its anxiogenic and depressive-like behavioral effects (clearly undesirable) — a meaningful obstacle to therapeutic development for weight loss.
• 06The functional roles of nesfatin-2 and nesfatin-3, the other NUCB2 cleavage products, which have been detected immunohistochemically but lack characterized biological activity.
• 07Whether the gastric NUCB2/nesfatin-1-expressing endocrine cell population (partially overlapping with ghrelin-producing X/A-like cells) represents a distinct enteroendocrine cell type with coordinated regulation of opposing hunger and satiety signals — a question with implications for gut-derived satiety pharmacology more broadly.

Forms & Administration

Nesfatin-1 is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic full-length nesfatin-1 (residues 1-82) or the active mid-segment fragment (approximately residues 24-53) for in vitro receptor binding and signaling assays, ex vivo tissue pharmacology, intracerebroventricular or peripheral (intraperitoneal, intravenous, subcutaneous) administration in animal models, and a small number of investigative human assays for plasma quantification. ELISA and radioimmunoassay kits for human and rodent NUCB2/nesfatin-1 are commercially available for research use, though inter-assay variability is a recognized concern in the literature. Compounded nesfatin-1 from peptide marketplaces has no validated clinical use.

Common Questions

Who Nesfatin-1 Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for nesfatin-1 because no nesfatin-1 product has been clinically developed and the receptor remains formally orphan. Theoretical interactions follow from documented signaling: insulinotropic activity in pancreatic beta cells raises theoretical concern for additive hypoglycemia with insulin, sulfonylureas, meglitinides, GLP-1 receptor agonists, and other glucose-lowering agents. Pressor and bradycardic cardiovascular effects in animal studies suggest theoretical interaction with antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers), with directional effects difficult to predict. Activation of the hypothalamic-pituitary-adrenal axis with elevation of plasma corticosterone or cortisol in animal studies raises theoretical concern for additive effects with exogenous corticosteroids. The oxytocin-receptor-mediated component of nesfatin-1's central effects could in principle interact with oxytocin (intranasal or peripartum) and oxytocin receptor antagonists (atosiban). Anxiogenic and depressive-like behavioral effects suggest theoretical interaction with antidepressants, anxiolytics, and other psychotropic medications. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous nesfatin-1 exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions